Author: Noris, Marina
Title: The case of complement inhibitors Cord-id: ho9cz64h Document date: 2021_8_19
ID: ho9cz64h
Snippet: Severe COVID-19 is characterized by lung and multiorgan inflammation and coagulation in the presence of overactivation of the complement system. Complement is a double edged-sward in SARS-Cov-2 infection. On one hand, it can control the viral infection in milder cases, on the other hand in cases with severe and prolonged infection massive complement activation occurs, which can intensify lung and systemic inflammation and promote a procoagulant and prothrombotic state. Several uncontrolled studi
Document: Severe COVID-19 is characterized by lung and multiorgan inflammation and coagulation in the presence of overactivation of the complement system. Complement is a double edged-sward in SARS-Cov-2 infection. On one hand, it can control the viral infection in milder cases, on the other hand in cases with severe and prolonged infection massive complement activation occurs, which can intensify lung and systemic inflammation and promote a procoagulant and prothrombotic state. Several uncontrolled studies and controlled clinical trials with different complement inhibitors have been performed and others are ongoing. Results are promising in some but negative in others. Further studies are required to elucidate the benefit to risk profile of complement inhibitors in COVID-19 patients at different stages of the disease and to clarify the best targets in the complement cascade.
Search related documents:
Co phrase search for related documents- activation pathway and acute sars infection: 1, 2, 3, 4, 5, 6, 7
- activation pathway and adaptive immune response: 1, 2, 3, 4, 5, 6, 7, 8, 9
- activation pathway and liver portal vein hepatic artery: 1, 2
- activation pathway and local complement activation: 1, 2
- activation pathway and logistic regression: 1
- activation pathway and lung damage: 1, 2, 3, 4, 5, 6, 7
- activation pathway and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- activation pathway and macrophage neutrophil: 1, 2
- activation viral clearance and acute ards respiratory distress syndrome: 1, 2, 3
- activation viral clearance and acute ards respiratory distress syndrome develop: 1
- activation viral clearance and acute sars infection: 1
- activation viral clearance and adaptive immune response: 1, 2, 3, 4, 5
- activation viral clearance and adaptive immune response activation viral clearance: 1, 2
- activation viral clearance and lung damage: 1
- activation viral clearance and lung injury: 1, 2
- activation viral clearance and macrophage neutrophil: 1
- acute ards respiratory distress syndrome and adaptive immune response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
- acute ards respiratory distress syndrome and adaptive phase: 1, 2
- acute ards respiratory distress syndrome and logistic regression: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
Co phrase search for related documents, hyperlinks ordered by date